Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

GT Biopharma (GTBP) Invested Capital (2016 - 2021)

GT Biopharma (GTBP) has disclosed Invested Capital for 12 consecutive years, with $32.2 million as the latest value for Q3 2021.

  • On a quarterly basis, Invested Capital rose 575.37% to $32.2 million in Q3 2021 year-over-year; TTM through Sep 2021 was $32.2 million, a 575.37% increase, with the full-year FY2020 number at -$29.0 million, down 375.98% from a year prior.
  • Invested Capital was $32.2 million for Q3 2021 at GT Biopharma, down from $37.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $557.2 million in Q2 2019 to a low of -$29.0 million in Q4 2020.
  • A 5-year average of $106.6 million and a median of $22.6 million in 2018 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: surged 58539.48% in 2017, then tumbled 375.98% in 2020.
  • GT Biopharma's Invested Capital stood at $521.3 million in 2017, then plummeted by 95.41% to $23.9 million in 2018, then crashed by 125.52% to -$6.1 million in 2019, then tumbled by 375.98% to -$29.0 million in 2020, then surged by 210.9% to $32.2 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Invested Capital are $32.2 million (Q3 2021), $37.1 million (Q2 2021), and $24.4 million (Q1 2021).